Glycyx Sheds Light on Opioid-Induced Immunotherapy Failure in Cancer Treatment
Glycyx highlights a new publication addressing opioid-induced immunotherapy failure in cancer treatment. The study provides insights into how opioids impair immune checkpoint inhibitor efficacy, supporting the development of their lead candidate, axelopran.
This news matters as it underscores the critical need to address the impact of opioids on cancer treatment outcomes. The research provides valuable insights into the mechanisms behind immunosuppression and tumor progression, ultimately aiming to improve the effectiveness of immunotherapy for cancer patients.
